| Literature DB >> 31929794 |
Baldeep K Mann1, Janpreet S Bhandohal1, Jungrak Hong1.
Abstract
This review summarizes the vast literature describing the long-term epidemiological studies with emphasis on postprandial glucose as a stronger predictor of cardiovascular complications as compared to fasting glucose and HbA1c. Many molecular studies also supported this fact by illustrating that postchallenge hyperglycemia is associated with elevated biomarkers of systemic inflammation in the plasma and thus increasing the chances of vascular damage. Large-scale studies have proved that vascular stiffness, brachial-ankle pulse-wave velocity, carotid intima thickness, and left ventricular hypertrophy have been associated with postprandial glucose as compared to fasting glucose or glycosylated hemoglobin.Entities:
Year: 2019 PMID: 31929794 PMCID: PMC6935819 DOI: 10.1155/2019/6048954
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Epidemiological studies describing the postprandial hyperglycemia as a predictor of cardiovascular mortality in various parts of the world for the last two decades.
| No. | Type of study | Name of the study | Total number of patients | Duration of follow-up (years) | Subject characteristics | Study outcome measured | Rate ratio | 95% CI |
|
|---|---|---|---|---|---|---|---|---|---|
| 1 | Prospective cohort | Sievers et al., 1999 [ | 1745 | 10.6 | Pima Indians with type 2 diabetes ≥15 years of age | 2-hour postprandial glucose (2 hPG) levels were associated with death rate from cardiovascular disease (CVD) | Death rate 1.2 | 1.1–1.4 | 0.007 |
|
| |||||||||
| 2 | Prospective cohort | de Vegt et al., 1999 [ | 2363 | 8 | Dutch subjects 50–75 years without known diabetes | Postload glucose predictive of increased cardiovascular mortality even within the nondiabetic range | Relative risk (RR) 3.4 | 1.35–8.53 | <0.05 |
|
| |||||||||
| 3 | Prospective cohort | Meigs et al., 2002 [ | 3370 | 4 | Subjects from the Framingham offspring study without clinical CVD or medication-treated diabetes | 2 hPG is associated with cardiovascular events | RR 1.14 | 1.02–1.27 | Not available |
|
| |||||||||
| 4 | Prospective cohort | Brunner et al., 2006 [ | 17869 | 33 | London-based male civil servants aged 40–64 years excluding those with known diabetes and with missing glucose measurements | 2 hPG associated with coronary heart disease | Hazard ratio (HR) 3.62 | 2.34–5.56 | Not available |
|
| |||||||||
| 5 | Prospective cohort | Meisinger et al., 2006 [ | 1160 | 30 | Randomly selected 40–59 year non-diabetic German subjects | 1-hour postload glucose (1 hPG) associated with all-cause mortality | HR 1.49 | 1.17–1.88 | Not available |
|
| |||||||||
| 6 | Prospective cohort (1974–1979) | Nigam et al., 2007 [ | 1691 | 14.7 | Patients with coronary artery disease (CAD) who were enrolled at 15 centers throughout North America | Postprandial hyperglycemia was not associated with cardiovascular mortality in patients with undiagnosed diabetes | HR 0.89 | 0.59–1.36 | Not available |
|
| |||||||||
| 7 | Prospective cohort | Chien et al., 2008 [ | 2165 | 10.5 | Chinese subjects in Taiwan aged ≥35 years | Postchallenge glucose was associated with major cardiovascular events | RR 2.05 | 1.23–3.42 | ≤0.001 |
|
| |||||||||
| 8 | Prospective cohort | Sarwar et al., 2010 [ | 18569 | 23.5 | Iceland subjects without history of diabetes and myocardial infarction (MI) | Postload glucose associated with coronary heart disease | HR 1.03 | 1.01–1.05 | Not available |
| 9 | Meta-analysis of 26 western prospective cohort studies | Sarwar et al., 2010 [ | 12652 | Not applicable | Not applicable | Postload glucose associated with coronary heart disease | RR 1.05 | 1.03–1.07 | Not available |
|
| |||||||||
| 10 | Prospective cohort | Kitada et al., 2010 [ | 422 | 2 | Acute MI (AMI) Japanese patients | 2 hPG was the only independent predictor of long-term major adverse cardiovascular events (MACE) two years after AMI | Odds ratio (OR) 1.85 | 1.07–3.21 | 0.028 |
|
| |||||||||
| 11 | Case control | Shimabukuro et al., 2011 [ | 287 | Not applicable | Japanese who visited the university hospital to be checked for glucose intolerance or known type 2 diabetes were consecutively recruited | Left ventricle dysfunction associated with impaired glucose tolerance | OR 3.43 | 1.09–11.2 | 0.037 |
|
| |||||||||
| 12 | Prospective cohort (HEART2D trial) | Raz et al., 2011 [ | 1115 | 2.7 | Patients with type 2 diabetes who survived of AMI | Patients using insulin targeting the postprandial versus fasting hyperglycemia had lower cardiovascular events | HR 0.69 | 0.49–0.96 | 0.029 |
|
| |||||||||
| 13 | Large prospective cohort (EpiDREAM study) | Anand et al., 2012 [ | 18,990 | 3.5 | 30–85 years multiethnic patients from 21 countries who had impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) levels | 2-hour post-OGTT glucose associated with increase in risk of cardiovascular events or death | HR 1.17 | 1.13–1.22 | Not available |
|
| |||||||||
| 14 | Prospective cohort | Tamita et al., 2012 [ | 275 | 5.3 | Japanese subjects with AMI | Abnormal glucose tolerance associated with MACE | HR 2.65 | 1.37–5.15 | 0.004 |
|
| |||||||||
| 15 | Prospective cohort | Furtado de Souza et al., 2012 [ | 148 | 36 ± 14 months | Brazilian subjects undergoing diabetes screening attending a primary care unit | 2-hour OGTT results were associated with CVD | OR 1.013 | 1.002–1.025 | 0.024 |
| 16 | 9 Finnish and Swedish prospective cohort | Ning et al., 2012 [ | 3743 men and 3916 women | 16.4 | 25 to 90 years who had fasting plasma glucose (FPG) < 6.1 mmol/l and 2 h PG < 7.8 mmol/l and free of CVD | 2 hPG associated with coronary heart disease | HR 1.13 in men; 1.33 in women | 0.93–1.37 in men; 0.83–2.13 in women | Not available |
|
| |||||||||
| 17 | Prospective cohort | Henareh and Agewall, 2012 [ | 123 | 6.03 ± 1.36 | Swedish subjects aged 31–80 years who had suffered a previous MI | 2 hPG was a significant predictor of cardiovascular death, recurrent MI, and unstable angina pectoris | HR 1.27 | 1.00–1.62 | <0.05 |
|
| |||||||||
| 18 | Prospective cohort | Silbernagel et al., 2012 [ | 1772 | 7.7 ± 2.0 | German nondiabetic subjects who were referred for angiography and whose FPG was <126 mg/dl underwent OGTT | Postchallenge glucose undetected by fasting glucose and glycated hemoglobin independently predicted the cardiovascular mortality | HR 1.57 | 1.02–2.43 | 0.041 |
|
| |||||||||
| 19 | Cross sectional (second strong heart study) | Capaldo et al., 2013 [ | 562 | Not applicable | American nondiabetic and nonhypertensive Indians of 45–74 years of age | Both higher IFG and IGT levels rather than only IFG associated with left ventricular hypertrophy | OR 9.76 | 2.03–46.79 | 0.004 |
|
| |||||||||
| 20 | Prospective cohort | Barzin et al., 2013 [ | 3794 | 8 | Tehran urban subjects aged ≥40 years without history of diabetes or CVD | Isolated postchallenge hyperglycemia associated with cardiovascular events | HR 1.77 | 1.19–2.64 | 0.005 |
|
| |||||||||
| 21 | Cross sectional | Yang et al., 2013 [ | 6040 | Not applicable | Chinese prediabetic subjects | CVD events associated with IGT levels compared to IFG levels | OR 2.88 | 1.36–6.01 | 0.0059 |
|
| |||||||||
| 22 | Prospective cohort | Kuramitsu et al., 2013 [ | 828 | 4.3 | Japanese patients of stable angina undergoing percutaneous intervention (PCI) | Postchallenge hyperglycemia was associated with MACE | HR 1.62 | 1.07–2.53 | 0.023 |
|
| |||||||||
| 23 | Finnish diabetes prevention prospective cohort study | Lind et al., 2014 [ | 504 | 13 | Finnish individuals with IGT were followed up with yearly OGTT, FPG, and HbA1c | 2 hPG was associated with CVD events | HR 2.19 | 1.51–3.18 | ≤0.001 |
| 24 | Prospective cohort | Ritsinger et al., 2015 [ | 167 AMI patients and 184 controls | 10 | Swedish patients up to 80 years with AMI ( | Patient with AMI having abnormal glucose tolerance after an OGTT performed at the time of discharge had higher cardiovascular mortality | HR 2.3 | 1.24–4.25 | 0.008 |
|
| |||||||||
| 25a | Yorkshire retrospective cohort | George et al., 2015 [ | 768 | 3 | Patients without pre-existing diabetes mellitus post-MI | IGT associated with increased incidence of MACE | HR 1.54 | 1.06–2.24 | 0.024 |
|
| |||||||||
| 25b | Yorkshire retrospective cohort study | George et al., 2015 [ | 768 | 3 | Patients without pre-existing diabetes mellitus post-MI | Newly diagnosed diabetes associated with increased incidence of MACE | HR 2.15 | 1.42–3.24 | 0.003 |
|
| |||||||||
| 26 | Prospective cohort | Faghihi-Kashani et al., 2016 [ | 2607 | 7.2 | Patients of type 2 diabetes mellitus in Tehran | 2 hPG was associated with high incidence of coronary heart disease | HR 1.64 | 1.03–2.61 | Not available |
|
| |||||||||
| 27 | Prospective cohort | Shahim et al., 2017 [ | 4004 | 2 | 24 European subjects aged ≥18–80 years hospitalized for a first or recurrent CAD event | 2 hPG associated with cardiovascular events | HR 1.38 | 1.07–1.78 | 0.01 |
|
| |||||||||
| 28 | Prospective cohort | Nielsen et al., 2017 [ | 4934 | 27 | Swedish subjects without diabetes | 1 hPG predicted the cardiovascular death | HR 1.09 | 1.01–1.17 | 0.02 |
|
| |||||||||
| 29 | Prospective cohort | Chattopadhyay et al., February 2018 [ | 674 | 4 | Post-MI survivors without known diabetes in England and Wales | Only 2 hPG predicted MACE | HR 1.12 | 1.04–1.20 | ≤0.001 |
|
| |||||||||
| 30 | Retrospective cohort | Chattopadhyay et al., August 2018 [ | 1056 | 40.8 months | Acute coronary event survivors without known diabetes mellitus who had FBG and 2 hPG measured predischarge | 2 hPG independently predicted MACE | HR 1.091 | 1.043–1.142 | ≤0.001 |
|
| |||||||||
| 31 | Cross sectional (CATAMERI study) | Fiorentino et al., 2019 [ | 1010 | Not applicable | Nondiabetic Caucasian individuals with hbA1c <5.7% | 1 hPG during OGTT ≥ 155 mg/dl associated with CAD | OR 6.16 | 1.05–36.32 | 0.04 |
|
| |||||||||
| 32 | Retrospective cohort | Chattopadhyay et al., 2019 [ | 1056 | 2.8 | MI survivors in East yorkshire and North Lincolnshire | 2 hPG predicted MACE-free survival | HR 1.16 | 1.07–1.26 | ≤0.001 |
Figure 1Graphical presentation of risks, hazard ratios, odds ratios, or mortality rates per study enlisted in Table 1 in temporal order.